Arcus Biosciences, Inc. RCUS
24.97
(0.09)
(0.36%)
as of 25 Sep
- Market cap
- $3.2B
- P/E
- 0.0×
Follow RCUS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (90.82%) | (69.95%) | (63.26%) | (68.13%) |
+8 more TTM periods Free account |
|
| (46.02%) | (34.28%) | (30.84%) | (30.64%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(77.44%) | (54.83%) | (43.26%) | (51.36%) | |
Average Days of Receivables |
112.31 | 4.64 | 16.26 | 16.73 | |
Free Cash Flow per Share |
(3.76) | (3.89) | (4.51) | (4.36) | |
Free Cash Flow |
(474.00) | (488.00) | (484.00) | (464.00) | |
Capital Expenditures |
— | — | (2.00) | (2.00) | |
Piotroski F-Score |
0.00 | 1.00 | 0.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(37.41%) | (33.75%) | (28.17%) | (33.85%) | |
Accounts Receivable Turnover |
4.59 | 26.22 | 15.94 | 17.78 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
424.79% | 221.61% | 211.74% | 209.58% | |
Selling, General and Administrative Expense of Revenue |
90.60% | 47.03% | 44.53% | 46.67% | |
Share Based Compensation of Revenue |
53.85% | 26.69% | 24.29% | 25.83% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.03 | 1.32 | 1.37 | 1.35 | |
Depreciation/Fixed assets |
0.00 | (0.08) | (0.07) | (0.14) | |
Capex/Depreciation |
— | 0.00 | 0.67 | 0.33 | |
Revenue per Share |
0.93 | 1.88 | 2.30 | 2.25 | |
Operating CF per Share |
(3.76) | (3.89) | (4.49) | (4.34) | |
Capex per Share |
0.00 | 0.00 | (0.02) | (0.02) | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.01 | |
Net Profit Margin |
(393.16%) | (156.36%) | (142.91%) | (142.08%) |
Columns are period end dates